Abstract：
Nanotechnology offers promising avenues for enhancing drug delivery systems, particularly in HIV-1 treatment. This study investigates a nanoemulsified formulation combining epigallocatechin gallate (EGCG) with dolutegravir (DTG) for managing HIV-1 infection. The combinatorial interaction between EGCG and DTG was explored through cellular, enzymatic, and molecular studies. In vitro assays demonstrated the potential of a dual drug-loaded nanoemulsion, NE-DTG-EGCG, in inhibiting HIV-1 replication, with EGCG serving as a supplementary treatment containing DTG. In silico molecular interaction studies highlighted EGCG\'s multifaceted inhibitory potential against HIV-1 integrase and reverse transcriptase enzymes. Further investigations are needed to validate the formulation\'s efficacy across diverse contexts. Overall, by integrating nanotechnology into drug delivery systems, this study represents a significant advancement in managing HIV-1 infection.
摘要：
纳米技术为增强药物输送系统提供了有希望的途径，特别是在HIV-1治疗中。这项研究调查了一种结合表没食子儿茶素没食子酸酯（EGCG）与dolutegravir（DTG）的纳米乳化制剂，用于管理HIV-1感染。EGCG和DTG之间的组合相互作用通过细胞，酶，和分子研究。体外试验证明了双重载药纳米乳液的潜力，NE-DTG-EGCG,抑制HIV-1复制，EGCG作为含有DTG的补充治疗。计算机分子相互作用研究强调了EGCG对HIV-1整合酶和逆转录酶的多方面抑制潜力。需要进一步的研究来验证配方在不同背景下的有效性。总的来说,通过将纳米技术整合到药物输送系统中，这项研究代表了在管理HIV-1感染方面的重大进展.
